Scout M Treadwell

Ms. Scout M Treadwell

Tulane University School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ENEmma Newton
Emma Newton
LMLauren Mueller
Lauren Mueller
Scout M TreadwellScout M Treadwell
Scout M Treadwell
CMCindy A. Morris
Cindy A. Morris
HMHeather L Machado
Heather L Machado
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Due to its heterogeneity and lack of hormone receptor expression, this subtype is more likely to metastasize and resist treatment attempts than are other forms of breast cancer. Due to the absence of targetable receptors, chemotherapy and breast conserving surgery have been the predominant treatment options for patients. However, resistance to chemotherapy and local recurrence of the tumors is frequent. Emerging immunotherapies have begun to change treatment plans for patients diagnosed with TNBC. In this review, we discuss the various immune pathways identified in TNBC and the role they play as targets for new potential treatment choices. Various therapeutic options that inhibit key pathways in cellular growth cycles, DNA repair mechanisms, epithelial mesenchymal transition, and immunosuppression have been shown to improve survival in patients with this disease. With promising results thus far, continued studies of immunotherapy and neoadjuvant therapy options for TNBC are likely to alter the treatment course for these diagnoses in the future.

4 April 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
Scout M TreadwellScout M Treadwell
Scout M Treadwell
MGMaxwell Green
Maxwell Green
AFAileen Feschuk
Aileen Feschuk
MVManuel Valdebran
Manuel Valdebran